|
 |
Phylogica has a strong intellectual property portfolio around its proprietary Phylomer® peptide technology with over eleven patent families comprising 25 granted/ allowed patents and 23 patent applications covering the markets of US, Europe, Japan, Australia and New Zealand (as of September 2007). Phylomer® peptides, being fragments of naturally occurring proteins sourced from ancient bacteria, have a different origin than antibodies and hence are not bound by traditional antibody patents.
Phylogica’s patent families cover methods of making the Phylomer® peptide libraries, methods of screening them and Phylomer® peptides discovered for therapeutic and diagnostic applications.
The Phylomer® peptide technology is available for licensing. For more information on partnering opportunities click here.
|
